Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amira Pharmaceuticals, a small molecule pharmaceutical company, has initiated a Phase I clinical study of AM211, its internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway.
Subscribe to our email newsletter
AM211 is an oral, selective antagonist of the receptor DP2, which recent studies have shown to be a potential target for the treatment of asthma, chronic obstructive pulmonary disease and allergic rhinitis. The Phase I study is designed to obtain safety and proof of mechanism data for AM211.
DP2 is also known as CRTH2 or chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes. DP2 is a high affinity receptor for prostaglandin D2 and, in humans, is implicated in Th2-dependent allergic inflammation.
Bob Baltera, CEO of Amira, said: “The start of the AM211 clinical studies marks another impressive milestone in our company’s short existence. Our small but effective team has been able to bring three distinct molecules into the clinic in less than four years. We look forward to continuing this pace as we advance our next program for idiopathic pulmonary fibrosis toward the clinic.”